Achieve Life Sciences, Inc. (ACHV) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $6.52: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 13.00; Below-average business quality.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with... Read more
Sell if holding. Engine safety override at $6.52: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 13.00; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Score 5.2/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — Achieve Life Sciences, Inc.
Latest news
- NEWS Achieve Life Sciences Added To Russell 2000 Index, Effective June 26 — benzinga Jun 29, 2026 positive
Generated 2026-07-05T07:10:30Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 7.6% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.52: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 13.00; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Prior stop was $5.95. Score 5.2/10, moderate confidence.
Take-profit target: $12.01 (+87.7% upside). Prior stop was $5.95. Stop-loss: $5.95.
Quality below floor (2.0 < 4.0); Value-trap signals (2/5): Margin compression (op margin -47.4%), High leverage (D/E 1.9).
Achieve Life Sciences, Inc. trades at a P/E of N/A (forward -12.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
14 analysts cover ACHV with a consensus score of 4.1/5. Average price target: $14.
What does Achieve Life Sciences, Inc. do?Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for...
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.